pTau 231
Early indicator of amyloid-β pathology with strong correlation to PET scan or CSF results.
Learn More ➔
Biomarker Assays for Neurological Disease
The SPEAR platform currently supports a portfolio of assays optimized for research in neurological diseases, including Alzheimer’s disease (AD), traumatic brain injury (TBI), multiple sclerosis (MS), and Amyotrophic lateral sclerosis (ALS). As part of workflows designed to identify and validate biomarkers, these assays provide sensitive, reliable quantification of targets associated with axonal damage, astrocyte activation, and tau pathology.
Kit Pairing
Assay Kit & Reaction Kit
Each SPEAR UltraDetect Assay Kits requires a universal SPEAR UltraDetect Reaction Kit
Each SPEAR UltraDetect Reaction Kit can support up to 4 SPEAR Ultra Detect Assay Kits
Kit Throughput
Each SPEAR UltraDetect Assay Kit can support 1 96-well plate
Each SPEAR UltraDetect Reaction Kit can support up to 4 96-well plates or 1 384-well plate
Benefits of SPEAR Assays
Attomolar biomarker measurement with 1 uL of diluted sample.
Two-factor authentication ensures target-specific signal.
No false positives from non-specific binding to a solid surface.
Easy-to-automate workflow with <5% mean CV from 1 µl of diluted sample.
Highly consistent measurement across different qPCR platforms and formats.
Discover SPEAR Assays
As the first ultrasensitive assay to combine a fully homogeneous format with two-factor authentication, SPEAR UltraDetect sets a new standard in protein biomarker detection.
